Michael Dixon
Managing Partner @ Transformation Capital
San Francisco, United States
Michael Dixon is a venture capitalist at Prior to joining Sequoia Capital in 2008, he worked at Fidelity Management & Research Company, where he directed $2 billion of investment capital in the wire and cable, ATM, and RFID sectors.Earlier, he was with UBS InvestmentBank and Deloitte. Michael has a BS in finance and accounting from Boston College. (Source :
- Total investments:
- 29
- Last investment:
- Lead investor:
- 41%
Last updated:
For AI agents: llms.txt
Industries Michael Dixon invests in
Stages Michael Dixon invests in
Countries Michael Dixon invests in
Investment Focus
Industry
- Health Care 9 (31%)
- Medical 4 (14%)
- Biotechnology 3 (10%)
- Employee Benefits 3 (10%)
- Hospital 2 (7%)
Stage
- Series B 6 (21%)
- Series C 6 (21%)
- Seed 2 (7%)
- Series A 2 (7%)
- Series D 2 (7%)
Country
- United States 13 (45%)
- Brazil 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Citizen Health
|
Over 350+ million people worldwide are affected by one of the 10,000+ rare diseases of which 95% do not have a single treatment available. Through our AI-powered platform, we liberate and structure data to radically improve rare and complex disease treatment, widen access to expert care, and revolutionize the development of new medicines at afraction of the speed previously proven possible. Patients can share their health data across our multi-sided platform with caregivers, providers and researchers to illuminate better treatment and support options, while bringing therapies to patients faster. We support thousands of patients, work with a rapidly growing network of patient advocacy organizations, and innovate with leading biopharma organizations to accelerate therapies, always ensuring patients remain at the center. | $30M / Series A / Aug 14, 2025 | |
Carecode
|
Carecode system combines powerful Generative AI models with continuous learning mechanisms, enabling natural and autonomous interactions that adapt to complicated environments without the need for human intervention. | $4.3M / Pre-Seed / Dec 30, 2024 | |
|
Citizen Health
|
Over 350+ million people worldwide are affected by one of the 10,000+ rare diseases of which 95% do not have a single treatment available. Through our AI-powered platform, we liberate and structure data to radically improve rare and complex disease treatment, widen access to expert care, and revolutionize the development of new medicines at afraction of the speed previously proven possible. Patients can share their health data across our multi-sided platform with caregivers, providers and researchers to illuminate better treatment and support options, while bringing therapies to patients faster. We support thousands of patients, work with a rapidly growing network of patient advocacy organizations, and innovate with leading biopharma organizations to accelerate therapies, always ensuring patients remain at the center. | $14.5M / Seed / Nov 19, 2024 | |
Amino
|
Amino is a San Francisco-based healthcare financial wellness platform that helps companies & their employees navigate the complexities of the US healthcare system & find the highest value care, which has become even more important of late. | $10M / Venture - Series Unknown / May 22, 2024 | |
|
Citizen Health
|
Over 350+ million people worldwide are affected by one of the 10,000+ rare diseases of which 95% do not have a single treatment available. Through our AI-powered platform, we liberate and structure data to radically improve rare and complex disease treatment, widen access to expert care, and revolutionize the development of new medicines at afraction of the speed previously proven possible. Patients can share their health data across our multi-sided platform with caregivers, providers and researchers to illuminate better treatment and support options, while bringing therapies to patients faster. We support thousands of patients, work with a rapidly growing network of patient advocacy organizations, and innovate with leading biopharma organizations to accelerate therapies, always ensuring patients remain at the center. | Seed / Dec 13, 2023 | |
|
Amino
|
Amino is a San Francisco-based healthcare financial wellness platform that helps companies & their employees navigate the complexities of the US healthcare system & find the highest value care, which has become even more important of late. | $38M / Venture - Series Unknown / May 11, 2023 | |
Nayya
|
At Nayya, we believe there’s a better way to choose and use benefits. A more transparent, less confusing way for employees to control their health and financial potential. Powered by billions of data points and machine learning, our benefits experience platform delivers personalized decision support and guidance during open enrollment, new employeeonboarding, qualifying life events, and in the moments that matter all year round. This is one of the most stressful and challenging situations consumers face – and we see that as an opportunity to build an innovative response that can help millions of Americans possess the control and understanding they deserve. Join the consumers and their employers that are now living with more peace and confidence at Nayya.com. | $55M / Series C / Mar 01, 2022 | |
Cleo
|
Cleo is the only global, holistic family care platform supporting individuals throughout every life stage. Whether individuals are growing their family, raising children or teenagers, caring for an adult loved one, doing both as part of the growing Sandwich Generation, or taking care of their own health, Cleo provides life-changing care forfamilies and caregivers. This is achieved through advanced analytics, virtual coaching, proactive concierge support, and navigation to community resources and benefits — so families can be happier and healthier both at home and at work. Serving more than 200 clients, Cleo provides global, equitable, and inclusive support with Guides located in every region of the world. With a focus on driving family health outcomes, Cleo provides real-time risk assessment, virtual coaching and concierge support for over 40 evidence-based care journeys called LifePaths, including cancer care, neurodivergence, menopause, and self-care. Cleo is proven to improve mental health and decrease burnout for members — as guaranteed by The Validation Institute — all while maximizing cost savings, increasing productivity, reducing healthcare spend, and improving the health & wellbeing of the family unit.For more information, visit www.hicleo.com. | $40M / Series C / Mar 30, 2021 | |
Datavant
|
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and sharing health data.The platform that the company offers organizes healthcare data for use in clinical trial decision-making. Its focus is on the employment of artificial intelligence to improve the clinical trial process and to improve thedesign and interpretation of clinical trials, helping pharmaceutical companies to manage the privacy, security, compliance, and trust required to enable safe data sharing.Travis May established Datavant in San Francisco, California in 2017. | $40M / Series B / Oct 08, 2020 | |
Mustard
|
Mustard is an elite-level motion analysis app for broad athletics coaching. Mustard's platform conducts complex data analysis of video captured in-app on a player or coach's mobile phone and delivers easily understandable report cards along with personalized, actionable drills to optimize performance. The robust AI technology andapplication suite, to expand into additional sports, and to build out an elite and robust mental performance training platform for all athletes.Mustard was founded in 2019 by Tom House, Jason Goldsmith, Luke Collis, and Rocky Collis. | $1.7M / Seed / Sep 04, 2020 | |
| See all 29 investments → | |||
Co-Investors
About Transformation Capital
Transformation Capital is the successor management company to Leerink Transformation Partners LLC (“LTP”).11 LTP was founded in 2016 by Todd Cozzens and Jared Kesselheim, MD together with SVB Leerink Capital LLC (formerly Leerink Capital Partners LLC) (“Leerink Capital”), an affiliate of SVB Leerink LLC (“Leerink”), a leading healthcare investmentbank. Leerink Capital provided seed capital to Fund I (approximately 3% of capital commitments) and operational support. In January 2019, SVB Financial Group (“SVB”), the holding company of Silicon Valley Bank, a U.S.-based high-tech commercial bank, acquired the Leerink businesses including Leerink Capital. Todd Cozzens, Jared Kesselheim, MD, and SVB expect to agree to a mutually beneficial ongoing relationship in which Transformation Capital (as an independent management company owned by Todd Cozzens, Jared Kesselheim, MD, and Michael Dixon and not affiliated with SVB or Leerink Capital) shall manage Fund II and whereby Transformation Capital shall manage Fund I’s investment portfolio pursuant to a sub-advisory agreement with SVB (or an affiliate). Transformation Capital has the same operational leader, Kevin Brown, formerly CFO of Leerink Capital, and Transformation Capital expects to continue to derive benefits from its ongoing relationship with Leerink and SVB.
Transformation Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jared Kesselheim
Co-Founder & Managing Partner
|
|||
Jenna Ciotti
Vice President
|
|||
Julie Murchinson
Partner
|
|||
|
Michael Dixon
Managing Partner
|
|||
Todd Cozzens
Co-Founder & Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael Dixon invest in?
Michael Dixon invests primarily in Health Care, Medical and Biotechnology startups, most often at Series B and Series C stage. Most of the 29 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Michael Dixon last invest?
The most recent investment recorded for Michael Dixon closed in Aug 2025. Shizune tracks 29 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
